This study hypothesized that combination of CHM and EGFR-TKIs may prolong PFS, increase tumor response, improve performance status, and reduce toxicities in advanced NSCLC patients harboring EGFR sensitizing mutation, compared with use of EGFR-TKIs alone. This evidence concerns the gene EGFR and neoplasm.